Seattle Genetics’ only marketed product is Adcetris (brentuximab vedotin). The drug is approved for relapsed Hodgkin lymphoma (HL) and relapsed systemic anaplastic large cell lymphoma (sALCL) in the United States, the EU and Japan.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,